[go: up one dir, main page]

BR9909173A - ácido nucleico, mutante de deleção de um alfa-vìrus, adenovìrus recombinante, vìrus vacìnia recombinante, plasmìdeo, vacina, e, processo para produzir uma imune resposta protetora a um alfa-vìrus - Google Patents

ácido nucleico, mutante de deleção de um alfa-vìrus, adenovìrus recombinante, vìrus vacìnia recombinante, plasmìdeo, vacina, e, processo para produzir uma imune resposta protetora a um alfa-vìrus

Info

Publication number
BR9909173A
BR9909173A BR9909173-9A BR9909173A BR9909173A BR 9909173 A BR9909173 A BR 9909173A BR 9909173 A BR9909173 A BR 9909173A BR 9909173 A BR9909173 A BR 9909173A
Authority
BR
Brazil
Prior art keywords
virus
alpha
vaccine
recombinant
nucleic acid
Prior art date
Application number
BR9909173-9A
Other languages
English (en)
Inventor
Catherine Susan Jacobs
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806525.3A external-priority patent/GB9806525D0/en
Application filed by Secr Defence filed Critical Secr Defence
Publication of BR9909173A publication Critical patent/BR9909173A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"áCIDO NUCLEICO, MUTANTE DE DELEçãO DE UM ALFA-VìRUS, ADENOVìRUS RECOMBINANTE, VìRUS VACìNIA RECOMBINANTE, PLASMìDEO, VACINA, E, PROCESSO PARA PRODUZIR UMA IMUNE RESPOSTA PROTETORA A UM ALFA-VìRUS". Um ácido nucleico que codifica um polipeptídeo que produz uma imune resposta protetora contra um alfa-vírus, tal como um Vírus da Encefalite Eq³ina Venezuelana, em um mamífero a que ele é administrado, dito ácido nucleico não tendo um competente sinal de marcação nuclear no gene capsídeo. Os ácidos nucleicos da invenção são expressos em níveis aumentados em vetores tais como os vetores do adenovírus. Em particular, é descrito um mutante de deleção de um alfa-vírus. Vetores tais como adenovírus recombinantes, que expressam o mutante de deleção são potencialmente de uso como vacinas.
BR9909173-9A 1998-03-27 1999-03-19 ácido nucleico, mutante de deleção de um alfa-vìrus, adenovìrus recombinante, vìrus vacìnia recombinante, plasmìdeo, vacina, e, processo para produzir uma imune resposta protetora a um alfa-vìrus BR9909173A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9806525.3A GB9806525D0 (en) 1998-03-27 1998-03-27 Recombinant virus
GBGB9825053.3A GB9825053D0 (en) 1998-03-27 1998-11-17 Recombinant virus
PCT/GB1999/000874 WO1999050292A1 (en) 1998-03-27 1999-03-19 Recombinant virus

Publications (1)

Publication Number Publication Date
BR9909173A true BR9909173A (pt) 2000-12-05

Family

ID=26313370

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909173-9A BR9909173A (pt) 1998-03-27 1999-03-19 ácido nucleico, mutante de deleção de um alfa-vìrus, adenovìrus recombinante, vìrus vacìnia recombinante, plasmìdeo, vacina, e, processo para produzir uma imune resposta protetora a um alfa-vìrus

Country Status (7)

Country Link
US (1) US6565853B1 (pt)
EP (1) EP1064305B1 (pt)
AT (1) ATE276271T1 (pt)
AU (1) AU2948599A (pt)
BR (1) BR9909173A (pt)
DE (1) DE69920192T2 (pt)
WO (1) WO1999050292A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US7309315B2 (en) * 2002-09-06 2007-12-18 Epoch Innovations, Ltd. Apparatus, method and computer program product to facilitate ordinary visual perception via an early perceptual-motor extraction of relational information from a light stimuli array to trigger an overall visual-sensory motor integration in a subject
DK2114459T3 (da) * 2007-02-23 2014-01-13 Ca Minister Nat Defence Rekombinante virusvektorer til forebyggelse af og beskyttelse mod alfavirusinfektion
US8691563B2 (en) 2008-07-17 2014-04-08 Medigen, Inc. IDNA vaccines and methods for using the same
EP2440251A4 (en) * 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
EP3407910B1 (en) 2016-01-29 2022-04-13 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
AU2017297610B2 (en) * 2016-07-15 2020-03-12 Etubics Corporation Compositions and methods for alphavirus vaccination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants

Also Published As

Publication number Publication date
ATE276271T1 (de) 2004-10-15
WO1999050292A1 (en) 1999-10-07
US6565853B1 (en) 2003-05-20
EP1064305A1 (en) 2001-01-03
DE69920192D1 (de) 2004-10-21
AU2948599A (en) 1999-10-18
EP1064305B1 (en) 2004-09-15
DE69920192T2 (de) 2005-09-29

Similar Documents

Publication Publication Date Title
DK0596979T3 (da) Rekombinante nucleinsyrer fra plantevirus
EP1064024A4 (en) VACCINES AGAINST CIRCOVIRUS INFECTIONS
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
BR9910814A (pt) Vacina para imunização terapêutica ou profilática contra vìrus da venezuelan equine encephalitis (vee), composição farmacêutica, processo para produção de uma resposta imune protetora contra vìrus vee em um mamìfero, e, vacina multivalente
WO1991011525A3 (en) Vaccines
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
DE69332831D1 (de) Rekombinanter schweinepocken-virus
BR9909173A (pt) ácido nucleico, mutante de deleção de um alfa-vìrus, adenovìrus recombinante, vìrus vacìnia recombinante, plasmìdeo, vacina, e, processo para produzir uma imune resposta protetora a um alfa-vìrus
BR9814204A (pt) "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
CN113226364A (zh) 组合物和方法
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
MY103854A (en) A recombinant marek''s disease virus and a vaccine.
PT988391E (pt) Vectores adenovirais recombinantes compreendendo uma sequencia de splicing
BR9812240A (pt) Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica
BR9912626A (pt) Mutante do herpesvìrus equino, sequência de ácido nucleico, molécula de dna recombinante, célula hospedeira, vacina, e, processos para a preparação de um mutante de ehv e para atenuar geneticamente o ehv
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
KR970703428A (ko) Hcmv 및 hsv로부터의 융합 당단백질(fusion glycoprotein from hcmv and hsv)
WO1997003187A3 (en) Marek's disease virus genes and their use in vaccines for protection against marek's disease
BR9915703A (pt) Mutante do vìrus da raiva recombinante, e, vacina anti-rábica atenuada viva
DK0675962T3 (da) Syntetiske herpessimplexviruspromotore
BR0016672A (pt) Constructo de vacina de ácido nucleico, composição de vacina, uso de um constructo de vacina de ácido nucleico, e, método de vacinação de um mamìfero contra tumores
AR014784A1 (es) Un acido nucleico que codifica un polipeptido que produce una respuesta protectora inmune contra un alfa-virus, una vacuna que lo comprende, su uso en la preparacion de medicamentos, un mutante de dicho alfavirus, un virus vaccinia y un plásmido
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
Amann et al. High-level production in Escherichia coli of hybrid proteins expressing parts of coding sequences of HSV glycoproteins.
KR910700352A (ko) 곤충 세포내에서 플라스모듐 서컴스포로 조이트 단백질의 발현

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Z Decision to grant cancelled [chapter 9.1.1 patent gazette]

Free format text: ANULADA A DECISAO DE DEFERIMENTO POR TER SIDO INDEVIDA REF. A RPI 2107 DE 24/05/2011.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements